T.Man Pharmaceutical Valuation

Q: What is the Fair Price of TMAN-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TMAN-R (THB16.9) is trading above our estimate of [[fair value]] (THB7.36)

Is TMAN-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TMAN-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TMAN-R (THB16.9) is trading above our estimate of fair value (THB7.36)

Significantly Below Fair Value: TMAN-R is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TMAN-R?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for TMAN-R. This is calculated by dividing TMAN-R's market cap by their current preferred multiple.
What is TMAN-R's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	฿6.76b

TMAN-R key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	11.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does TMAN-R's PE Ratio compare to its peers?

The above table shows the PE ratio for TMAN-R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.5x
BLC Bangkok Lab And Cosmetic	19.3x	n/a	฿3.1b
MEGA Mega Lifesciences	16.7x	11.7%	฿33.3b
JSP JSP Pharmaceutical Manufacturing (Thailand) Public	44.1x	n/a	฿968.1m
AFT AFT Pharmaceuticals	22x	26.7%	NZ$344.0m
TMAN-R T.Man Pharmaceutical	16.1x	n/a	฿6.8b

Price-To-Earnings vs Peers: TMAN-R is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (25.5x).

Price to Earnings Ratio vs Industry

How does TMAN-R's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.7%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: TMAN-R is good value based on its Price-To-Earnings Ratio (16.1x) compared to the Asian Pharmaceuticals industry average (25.8x).

Price to Earnings Ratio vs Fair Ratio

What is TMAN-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TMAN-R PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMAN-R's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.